Biotherapeutics Inc said its
cooperative findings on interleukin-2, the anti-cancer drug,
were published today in the "New England Journal of Medicine".
    Biotherapeutics, along with the Biological Therapy
Institute and the National Cancer Institute, said the
publication focused on a reduction in toxicity through the use
of a constant infusion mode of intravenous administration
protocol.
 Reuter
&#3;